Clinical Trials Browser

Active not recruiting × Hematologic Diseases × isatuximab × Clear all

NCT04786028 2025-01-08

A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM

Phase 2 Active not recruiting

Hematologic Diseases, Multiple Myeloma, Neoplasms